Deirdre Egan

Predictors of Kidney Tubular Dysfunction in HIV‐Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Sonia Rodríguez‐Nóvoa, Pablo Labarga, Vincent Soriano et al. · Clinical Infectious Diseases · 2009 · 241 citations · Full text

Medicine, Infectious Diseases, Nephrology +17

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

Ruben C. Hartkoorn, Wai San Kwan, Victoria Shallcross et al. · Pharmacogenetics and Genomics · 2010 · 175 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

Emmanuel Chigutsa, Marianne E Visser, Paolo Denti et al. · Antimicrobial Agents and Chemotherapy · 2011 · 147 citations · Full text

Veterinary Medicine, Pharmacokinetics, Pharmacology +16

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

Akil Jackson, Laura Else, Pedro M. M. Mesquita et al. · Clinical Pharmacology & Therapeutics · 2014 · 103 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Laura Dickinson, Janaki Amin, Laura Else et al. · Clinical Pharmacology & Therapeutics · 2015 · 74 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17